Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):484–488. doi: 10.1128/aac.39.2.484

Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms.

J B McMahon 1, M J Currens 1, R J Gulakowski 1, R W Buckheit Jr 1, C Lackman-Smith 1, Y F Hallock 1, M R Boyd 1
PMCID: PMC162564  PMID: 7537029

Abstract

Studies of the mechanism of action of michellamine B, a novel anti-human immunodeficiency virus (HIV) alkaloid from the tropical plant Ancistrocladus korupensis, have revealed that the compound acts at two distinct stages of the HIV life cycle. The compound had no direct effect on HIV virions and did not block the initial binding of HIV to target cells. Postinfection time course studies revealed that the agent partially inhibited HIV-induced cell killing and syncytium formation when added up to 48 h following acute infection; however, viral reproduction was fully inhibited only when the compound was added immediately after infection. Time-limited treatments of HIV-infected cells revealed that michellamine B had to be present continuously to provide maximum antiviral protection. HIV replication in cells in which infection was already fully established or in chronically infected cells was unaffected by michellamine B. Biochemical studies showed that michellamine B inhibited the enzymatic activities of reverse transcriptases (RTs) from both HIV type 1 and HIV type 2 as well as two different nonnucleoside drug-resistant RTs with specific amino acid substitutions. In addition, human DNA polymerases alpha and beta were inhibited by the alkaloid. Michellamine B exerted a potent dose-dependent inhibition of cell fusion in two independent cell-based fusion assays. Thus, michellamine B acts both at an early stage of the HIV life cycle by inhibiting RT as well as at later stages by inhibiting cellular fusion and syncytium formation.

Full Text

The Full Text of this article is available as a PDF (230.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bader J. P., McMahon J. B., Schultz R. J., Narayanan V. L., Pierce J. B., Harrison W. A., Weislow O. S., Midelfort C. F., Stinson S. F., Boyd M. R. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6740–6744. doi: 10.1073/pnas.88.15.6740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beutler J. A., Cardellina J. H., 2nd, McMahon J. B., Boyd M. R., Cragg G. M. Anti-HIV and cytotoxic alkaloids from Buchenavia capitata. J Nat Prod. 1992 Feb;55(2):207–213. doi: 10.1021/np50080a008. [DOI] [PubMed] [Google Scholar]
  3. Boyd M. R., Hallock Y. F., Cardellina J. H., 2nd, Manfredi K. P., Blunt J. W., McMahon J. B., Buckheit R. W., Jr, Bringmann G., Schäffer M., Cragg G. M. Anti-HIV michellamines from Ancistrocladus korupensis. J Med Chem. 1994 Jun 10;37(12):1740–1745. doi: 10.1021/jm00038a003. [DOI] [PubMed] [Google Scholar]
  4. Boyer P. L., Currens M. J., McMahon J. B., Boyd M. R., Hughes S. H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J Virol. 1993 Apr;67(4):2412–2420. doi: 10.1128/jvi.67.4.2412-2420.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Boyer P. L., Ferris A. L., Hughes S. H. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J Virol. 1992 Feb;66(2):1031–1039. doi: 10.1128/jvi.66.2.1031-1039.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Buckheit R. W., Jr, Hollingshead M. G., Germany-Decker J., White E. L., McMahon J. B., Allen L. B., Ross L. J., Decker W. D., Westbrook L., Shannon W. M. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Res. 1993 Jul;21(3):247–265. doi: 10.1016/0166-3542(93)90031-d. [DOI] [PubMed] [Google Scholar]
  7. Buckheit R. W., Jr, Swanstrom R. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res Hum Retroviruses. 1991 Mar;7(3):295–302. doi: 10.1089/aid.1991.7.295. [DOI] [PubMed] [Google Scholar]
  8. Ciminale V., Felber B. K., Campbell M., Pavlakis G. N. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res Hum Retroviruses. 1990 Nov;6(11):1281–1287. doi: 10.1089/aid.1990.6.1281. [DOI] [PubMed] [Google Scholar]
  9. Condra J. H., Emini E. A., Gotlib L., Graham D. J., Schlabach A. J., Wolfgang J. A., Colonno R. J., Sardana V. V. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother. 1992 Jul;36(7):1441–1446. doi: 10.1128/aac.36.7.1441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gulakowski R. J., McMahon J. B., Staley P. G., Moran R. A., Boyd M. R. A semiautomated multiparameter approach for anti-HIV drug screening. J Virol Methods. 1991 Jun;33(1-2):87–100. doi: 10.1016/0166-0934(91)90010-w. [DOI] [PubMed] [Google Scholar]
  11. Gustafson K. R., Cardellina J. H., 2nd, McMahon J. B., Gulakowski R. J., Ishitoya J., Szallasi Z., Lewin N. E., Blumberg P. M., Weislow O. S., Beutler J. A. A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978–1986. doi: 10.1021/jm00089a006. [DOI] [PubMed] [Google Scholar]
  12. Hizi A., McGill C., Hughes S. H. Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1218–1222. doi: 10.1073/pnas.85.4.1218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hizi A., Tal R., Hughes S. H. Mutational analysis of the DNA polymerase and ribonuclease H activities of human immunodeficiency virus type 2 reverse transcriptase expressed in Escherichia coli. Virology. 1991 Jan;180(1):339–346. doi: 10.1016/0042-6822(91)90038-d. [DOI] [PubMed] [Google Scholar]
  14. Kashman Y., Gustafson K. R., Fuller R. W., Cardellina J. H., 2nd, McMahon J. B., Currens M. J., Buckheit R. W., Jr, Hughes S. H., Cragg G. M., Boyd M. R. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem. 1992 Jul 24;35(15):2735–2743. doi: 10.1021/jm00093a004. [DOI] [PubMed] [Google Scholar]
  15. Kimpton J., Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol. 1992 Apr;66(4):2232–2239. doi: 10.1128/jvi.66.4.2232-2239.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992 Jun 26;256(5065):1783–1790. doi: 10.1126/science.1377403. [DOI] [PubMed] [Google Scholar]
  17. Manfredi K. P., Blunt J. W., Cardellina J. H., 2nd, McMahon J. B., Pannell L. L., Cragg G. M., Boyd M. R. Novel alkaloids from the tropical plant Ancistrocladus abbreviatus inhibit cell killing by HIV-1 and HIV-2. J Med Chem. 1991 Dec;34(12):3402–3405. doi: 10.1021/jm00116a011. [DOI] [PubMed] [Google Scholar]
  18. McMahon J. B., Gulakowski R. J., Weislow O. S., Schultz R. J., Narayanan V. L., Clanton D. J., Pedemonte R., Wassmundt F. W., Buckheit R. W., Jr, Decker W. D. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1993 Apr;37(4):754–760. doi: 10.1128/aac.37.4.754. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nunberg J. H., Schleif W. A., Boots E. J., O'Brien J. A., Quintero J. C., Hoffman J. M., Emini E. A., Goldman M. E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991 Sep;65(9):4887–4892. doi: 10.1128/jvi.65.9.4887-4892.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Parker W. B., White E. L., Shaddix S. C., Ross L. J., Buckheit R. W., Jr, Germany J. M., Secrist J. A., 3rd, Vince R., Shannon W. M. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J Biol Chem. 1991 Jan 25;266(3):1754–1762. [PubMed] [Google Scholar]
  21. White E. L., Buckheit R. W., Jr, Ross L. J., Germany J. M., Andries K., Pauwels R., Janssen P. A., Shannon W. M., Chirigos M. A. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257–266. doi: 10.1016/0166-3542(91)90005-c. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES